Previous 10 | Next 10 |
Stoke Therapeutics Inc. (STOK) is expected to report $-0.65 for Q3 2023
2023-11-07 08:25:29 ET More on Stoke Therapeutics Stoke Therapeutics Is Unable To Derisk Its Platform Seeking Alpha’s Quant Rating on Stoke Therapeutics Historical earnings data for Stoke Therapeutics Financial information for Stoke Therapeutics ...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will participate in a panel presentation at the 2023 Cantor Global Health...
– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe di...
2023-09-10 17:08:27 ET Summary Stoke Therapeutics (STOK) stock is down 40% after failing to meet expectations in a phase 1/2 epilepsy trial. STOK develops therapies for rare diseases using its TANGO approach, but its high valuation and limited market space pose challenges. The...
– Data from multiple ongoing clinical studies of STK-001 show reductions in convulsive seizure frequency and improvements in cognition and behavior in children and adolescents with Dravet syndrome – – Data support the potential for STK-001 to be the first disease-...
2023-08-16 13:00:00 ET If you're looking for a hidden gem in the biotech sector, you might want to check out Stoke Therapeutics (NASDAQ: STOK) . This company is developing innovative therapies for rare genetic diseases that represent a high degree of unmet medical need. And acco...
2023-08-07 07:20:38 ET Stoke Therapeutics press release ( NASDAQ: STOK ): Q2 GAAP EPS of -$0.69 misses by $0.06 . As of June 30, 2023, Stoke had approximately $231.4 million in cash, cash equivalents, and marketable securities, which is anticipated to fund operations t...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the Canaccord Genuity 43rd Annual Growth Conference on We...
2023-07-28 17:39:07 ET Gainers: Annexon ( ANNX ) +5% . Fluence Energy ( FLNC ) +4% . Humacyte ( HUMA ) +3% . Stoke Therapeutics ( STOK ) +3% . Brightcove ( BCOV ) +3% . Losers: Silk Road Medical ( SILK ) -5% . ...
News, Short Squeeze, Breakout and More Instantly...
Stoke Therapeutics Inc. Company Name:
STOK Stock Symbol:
NYSE Market:
Stoke Therapeutics Inc. Website:
2024-06-16 20:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldma...
2024-05-16 08:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...